Market Outlook


  • Abigail Doolittle, Peak Theories, and Kenny Polcari, O'Neil Securities, share their thoughts on how investors should position themselves as markets near all-time highs.

  • El Nino commodity risk     Tuesday, 22 Apr 2014 | 1:30 PM ET

    CNBC'S Jane Wells takes a look at commodities that have historically been vulnerable to El Nino price shock.

  • It's all about earnings     Tuesday, 22 Apr 2014 | 1:23 PM ET

    Wasif Latif, USAA Investments, and David Donabedian,Atlantic Trust, share their outlook on the markets and the economy, as the Nasdaq is poised to post a sixth straight day of gains.

  • Individual investor comeback?     Tuesday, 22 Apr 2014 | 1:00 PM ET

    CNBC's Jeff Cox discusses some of the clues he found that suggest when the individual investor is going to start getting into the market.

  • Betting on Meg Whitman: Whitworth     Tuesday, 22 Apr 2014 | 11:39 AM ET

    CNBC's David Faber and activist investor Ralph Whitworth, Relational Investors founder and principal, discuss the job Meg Whitman is doing turning around Hewlett-Packard.

  • European markets close: Pharma in focus     Tuesday, 22 Apr 2014 | 11:30 AM ET

    CNBC's Simon Hobbs reports on all the market moving events in Europe today, including consumer confidence in the euro zone and a spike in the biotech and pharma sectors.

  • The Netflix model will be pursued by everybody, says investor Kevin O'Leary, discussing the market outlook for Netflix and the company's move to raise prices for new subscribers.

  • Aereo found loophole in law: O'Leary     Tuesday, 22 Apr 2014 | 11:02 AM ET

    Investor Kevin O'Leary of "Shark Tank," weighs in on Aereo's landmark Supreme Court case and the future of broadcasting. O'Leary also shares his thoughts on net neutrality.

  • CNBC's David Faber and Jeffrey Ubben, ValueAct Capital Partners CEO, discuss the job performance of Microsoft CEO Satya Nadella and the likelihood of the Nokia deal closing.

  • Allergan, Valeant perfect match: CEO     Tuesday, 22 Apr 2014 | 10:48 AM ET

    CNBC's David Faber and Jeffrey Ubben, ValueAct Capital Partners CEO, discuss Valeant Pharmaceuticals bid for Allergan and why Valeant needed investor Bill Ackman involved in the deal.

  • McDonald's needs US to turn positive: Analyst     Tuesday, 22 Apr 2014 | 10:24 AM ET

    Discussing McDonald's positive European profits and need for margin improvement in the U.S., with Jeffrey Bernstein, Barclays senior restaurant analyst.

  • Evolution of the activist investor     Tuesday, 22 Apr 2014 | 10:12 AM ET

    CNBC's David Faber speaks with Keith Meister, Corvex Management managing partner, about the role and engagement of the activist investor and shares his thoughts on Valeant Pharmaceuticals bid for Allergan.

  • People like Netflix as much as HBO: Analyst     Tuesday, 22 Apr 2014 | 10:04 AM ET

    Discussing Netflix earnings growth and the company's continued investment in content, with Barton Crockett, FBR Capital Markets senior analyst.

  • The Netflix ecosystem     Tuesday, 22 Apr 2014 | 9:17 AM ET

    The "Squawk on the Street" news team discusses Netflix's quarterly earnings and competition from Amazon.

  • Novartis strikes multiple deals     Tuesday, 22 Apr 2014 | 9:09 AM ET

    The "Squawk on the Street" news team discuss all the M&A activity going on in pharma after Novartis is reported to be purchasing GlaxoSmithKline's oncology products unit for $14.5 billion. Separately Novartis is selling its animal health division to Eli Lilly for $5.4 billion in cash.

  • Close look at Allergan bid     Tuesday, 22 Apr 2014 | 9:01 AM ET

    The "Squawk on the Street" news team discuss the legality of activist investor Bill Ackman backing the bid of Valeant Pharmaceuticals to acquire Allergan.

  • Don't start your trading day without finding out what CNBC's Jim Cramer is watching ahead of the opening bell.

  • What the market's signaling     Tuesday, 22 Apr 2014 | 7:10 AM ET

    Discussing current market conditions, and how the activist investor is changing the conversation in the board room, with Julian Emanuel, UBS, and Charles Kantor, Neuberger Berman.

  • Correction over, buy the market: Pro     Tuesday, 22 Apr 2014 | 6:34 AM ET

    Dissecting current market action, and the building M&A cycle, with Mary Ann Bartels, Merrill Lynch Wealth Management. "We think capex will be the next step for investing," she explains.

  • Gartman sounds the all clear for stocks Monday, 21 Apr 2014 | 6:33 PM ET
    Dennis Gartman

    Dennis Gartman is back to buying stocks and is "pleasantly long" on the market after bailing out in early April.

Most Popular Video

Tuesday, 22 Apr 2014 | 10:48 PM ET

Todd Elmer, Currency Strategist at Citi, discusses whether the currency's sharp drop following weaker-than-expected quarterly inflation data was justified.

Tuesday, 22 Apr 2014 | 10:30 PM ET

Adaire Fox-Martin, COO, Asia Pacific Japan at SAP, elaborates on the firm's "stunning results" in Southeast Asia, India and the sector of cloud computing in the first-quarter.

Tuesday, 22 Apr 2014 | 10:17 PM ET

Joe Magyer, Senior Analyst at The Motley Fool, says the flurry of activity on Wall Street looks "frothy" at the moment.